Esophageal Cancer Clinical Trials 2023

Browse 100 Esophageal Cancer Medical Studies Across 356 Cities

12 Phase 3 Trial · 912 Esophageal Cancer Clinics

Reviewed by Michael Gill, B. Sc.
10 Esophageal Cancer Clinical Trials Near Me
Top Hospitals for Esophageal Cancer Clinical Trials
Image of M D Anderson Cancer Center in Texas.
M D Anderson Cancer Center
Houston
13Active Trials
24All Time Trials for Esophageal Cancer
2003First Esophageal Cancer Trial
Image of Washington University School of Medicine in Missouri.
Washington University School of Medicine
Saint Louis
7Active Trials
18All Time Trials for Esophageal Cancer
2005First Esophageal Cancer Trial
Image of Moffitt Cancer Center in Florida.
Moffitt Cancer Center
Tampa
6Active Trials
7All Time Trials for Esophageal Cancer
2002First Esophageal Cancer Trial
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
5Active Trials
23All Time Trials for Esophageal Cancer
2002First Esophageal Cancer Trial
Image of University of California Davis Comprehensive Cancer Center in California.
University of California Davis Comprehensive Cancer Center
Sacramento
5Active Trials
8All Time Trials for Esophageal Cancer
2011First Esophageal Cancer Trial
Top Cities for Esophageal Cancer Clinical Trials
Image of New York in New York.
New York
27Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site
Image of Houston in Texas.
Houston
25Active Trials
M D Anderson Cancer CenterTop Active Site
Esophageal Cancer Clinical Trials by Phase of TrialEsophageal Cancer Clinical Trials by Age GroupMost Recent Esophageal Cancer Clinical TrialsTop Treatments for Esophageal Cancer Clinical Trials
Treatment Name
Active Esophageal Cancer Clinical Trials
All Time Trials for Esophageal Cancer
First Recorded Esophageal Cancer Trial
Treatment
10
10
1997
Pharmacological Study
3
5
2010
Nivolumab
3
22
2015
Pembrolizumab
3
31
2014
Itraconazole
3
3
2016
Recently Completed Studies with FDA Approved Treatments for Esophageal Cancer
Treatment
Year
Sponsor
M1231
2021
EMD Serono Research & Development Institute, Inc.
Pembrolizumab
2019
City of Hope Medical Center
Fine-Needle Aspiration
2018
Sidney Kimmel Cancer Center at Thomas Jefferson University
Pembrolizumab
2018
M.D. Anderson Cancer Center
Oxaliplatin+Capecitabine+Pembrolizumab
2018
Duke University
Pembrolizumab
2017
Merck Sharp & Dohme LLC
Pembrolizumab
2017
Dana-Farber Cancer Institute

What Are Esophageal Cancer Clinical Trials?

Esophageal cancer is a disease that starts in the esophagus, a long tube-like muscle that runs from the throat into the stomach. The disease commonly starts forming in the cells lining the inside of the esophagus, however it may occur anywhere along the esophagus. Since esophageal cancer is the sixth most common cause of cancer deaths globally, scientists are ramping up esophageal cancer clinical trials to help with diagnosis and treatment.

The most common risk factors for esophageal cancer are the consumption of tobacco and alcohol. Older adults may be more likely to encounter esophageal cancer. The disease is usually asymptomatic until it spreads throughout the esophagus and other body parts. This is why regular tests are essential for discovering cancer at an early stage.

Why Is Esophageal Cancer Being Studied Through Clinical Trials?

Esophageal cancer clinical trials are important for improving the cancer's detection, prevention, and treatment while also ensuring that patients have a better quality of life. Clinical trials also identify the primary causes of esophageal cancer and discover more effective methods of treatment and diagnosis.

Diagnosis, in particular, plays a key role in managing the disease at an early stage. Because most esophageal cases are asymptomatic, people are commonly advised to get tested regularly. Advanced treatments are aimed at diminishing the impact of esophageal cancer and harnessing the body's ability to heal itself.

What Are The Types of Treatments Available for Esophageal Cancer?

Knowing how far the cancer has spread is important before planning treatment. Doctors will prescribe various tests and procedures to help them make informed decisions, including CT scans, endoscopic ultrasounds, PET scans, and MRIs. The cancer staging system evolves as more esophageal cancer clinical trials improve diagnosis and treatment.

The first course of action is surgery to remove tumors, followed by chemotherapy to kill any remaining cancer cells. Radiation therapy may be used with chemotherapy. Finally, the patient will be prescribed drugs to kill cancer cells and boost their immune system.

What Are Some Recent Breakthrough Clinical Trials For Esophageal Cancer?

The following studies indicate progress in diagnosing, treating, and managing Esophageal Cancer.

2008 - Recent Advances in Esophageal Cancer Chemotherapy - This study is based on various esophageal cancer clinical trials, including monoclonal antibodies and signal transduction for EGFR. It studied response rates of drug combinations and chemotherapy for managing the cancer.

2019 - Immunotherapy in Esophageal Cancer: This study evaluated several clinical trials to establish a multimodal radiation therapy for esophageal cancer, including immunotherapy.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Esophageal Cancer Trial Research?

David H. Ilson is a medical oncologist who has been consistently recognized as a top doctor by New York Magazine. He conducted esophageal cancer clinical trials by collecting the T cells of patients and developing new treatments.

Geoffrey Y. Ku is an eminent medical oncologist at the Memorial Sloan Kettering Cancer Center, specializing in various types of cancer, including esophageal and pancreatic cancers.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: August 15th, 2023

References1 Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027. https://pubmed.ncbi.nlm.nih.gov/201895032 van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088. https://pubmed.ncbi.nlm.nih.gov/226466303 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. https://pubmed.ncbi.nlm.nih.gov/224378704 Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027. No abstract available. https://pubmed.ncbi.nlm.nih.gov/201895035 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. Review. https://pubmed.ncbi.nlm.nih.gov/224378706 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30. https://pubmed.ncbi.nlm.nih.gov/260282557 Zhang X, Schwartz JC, Guo X, Bhatia S, Cao E, Lorenz M, Cammer M, Chen L, Zhang ZY, Edidin MA, Nathenson SG, Almo SC. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004 Mar;20(3):337-47. Erratum in: Immunity. 2004 May;20(5):651. https://pubmed.ncbi.nlm.nih.gov/150307778 Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, Demaria S, Formenti SC. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015 Jul;16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6. Epub 2015 Jun 18. https://pubmed.ncbi.nlm.nih.gov/260957859 Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jager N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, Lopez-Otin C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdes-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain; Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14. Erratum In: Nature. 2013 Oct 10;502(7470):258. Imielinsk, Marcin [corrected to Imielinski, Marcin]. https://pubmed.ncbi.nlm.nih.gov/2394559210 Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5. https://pubmed.ncbi.nlm.nih.gov/26254683